$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000106282215000032 Filed on August 07, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$376.0K	$676.0K
YoY Change	-44.38%	215.89%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.300M	$5.000M
YoY Change	26.0%	6.38%
% of Gross Profit
Research & Development	$20.77M	$21.19M
YoY Change	-1.97%	-10.57%
% of Gross Profit
Depreciation & Amortization	$200.0K	$600.0K
YoY Change	-66.67%	-25.0%
% of Gross Profit
Operating Expenses	$27.06M	$26.79M
YoY Change	1.03%	-7.11%
Operating Profit	-$26.69M	-$26.11M
YoY Change	2.21%	-8.78%
Interest Expense	$1.655M	$455.0K
YoY Change	263.74%	-8.27%
% of Operating Profit
Other Income/Expense, Net	$269.0K	$538.0K
YoY Change	-50.0%	-13550.0%
Pretax Income	-$28.10M	-$26.00M
YoY Change	8.08%	-10.65%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$28.07M	-$26.03M
YoY Change	7.86%	-10.5%
Net Earnings / Revenue	-7466.49%	-3850.3%
Basic Earnings Per Share	-$0.27
Diluted Earnings Per Share	-$0.27	-$353.7K
COMMON SHARES
Basic Shares Outstanding	103.6M shares	514.9M shares
Diluted Shares Outstanding	103.6M shares

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$282.1M	$78.60M
YoY Change	258.91%	-55.06%
Cash & Equivalents	$9.744M	$27.73M
Short-Term Investments	$272.3M	$50.90M
Other Short-Term Assets	$7.151M	$7.342M
YoY Change	-2.6%	9.84%
Inventory
Prepaid Expenses
Receivables	$316.0K	$281.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$313.8M	$86.67M
YoY Change	262.07%	-52.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$684.0K	$39.18M
YoY Change	-98.25%	-7.06%
Goodwill	$44.54M	$44.54M
YoY Change	0.0%	0.0%
Intangibles	$53.36M	$53.56M
YoY Change	-0.37%	0.0%
Long-Term Investments
YoY Change
Other Assets	$3.581M	$120.0K
YoY Change	2884.17%	84.62%
Total Long-Term Assets	$102.2M	$137.4M
YoY Change	-25.64%	-2.08%
TOTAL ASSETS
Total Short-Term Assets	$313.8M	$86.67M
Total Long-Term Assets	$102.2M	$137.4M
Total Assets	$416.0M	$224.1M
YoY Change	85.65%	-30.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.29M	$8.350M
YoY Change	35.22%	32.94%
Accrued Expenses	$10.81M	$10.89M
YoY Change	-0.73%	-3.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.26M	$1.783M
YoY Change	979.92%	-92.14%
Total Short-Term Liabilities	$43.57M	$21.90M
YoY Change	98.99%	-46.47%
LONG-TERM LIABILITIES
Long-Term Debt	$87.50M	$19.26M
YoY Change	354.43%
Other Long-Term Liabilities	$23.04M	$34.82M
YoY Change	-33.84%	-1.23%
Total Long-Term Liabilities	$110.5M	$54.08M
YoY Change	104.41%	53.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.57M	$21.90M
Total Long-Term Liabilities	$110.5M	$54.08M
Total Liabilities	$184.5M	$107.4M
YoY Change	71.78%	-0.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.160B	-$1.061B
YoY Change	9.39%	11.09%
Common Stock	$104.0K	$516.0K
YoY Change	-79.84%	0.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.747M	$2.390M
YoY Change	14.94%	59.02%
Treasury Stock Shares	237.0K shares	1.281M shares
Shareholders Equity	$231.5M	$116.7M
YoY Change
Total Liabilities & Shareholders Equity	$416.0M	$224.1M
YoY Change	85.65%	-30.71%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$28.07M	-$26.03M
YoY Change	7.86%	-10.5%
Depreciation, Depletion And Amortization	$200.0K	$600.0K
YoY Change	-66.67%	-25.0%
Cash From Operating Activities	-$32.20M	-$19.70M
YoY Change	63.45%	-6.64%
INVESTING ACTIVITIES
Capital Expenditures	-$500.0K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$800.0K	$1.200M
YoY Change	-33.33%	-88.99%
Cash From Investing Activities	$300.0K	$1.200M
YoY Change	-75.0%	-88.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-400.0K	-400.0K
YoY Change	0.0%	33.33%
NET CHANGE
Cash From Operating Activities	-32.20M	-19.70M
Cash From Investing Activities	300.0K	1.200M
Cash From Financing Activities	-400.0K	-400.0K
Net Change In Cash	-32.30M	-18.90M
YoY Change	70.9%	71.82%
FREE CASH FLOW
Cash From Operating Activities	-$32.20M	-$19.70M
Capital Expenditures	-$500.0K	$0.00
Free Cash Flow	-$31.70M	-$19.70M
YoY Change	60.91%	-4.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Interest Expense InterestExpense	912000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	103613400	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE
CY2015Q2	lxrx	Buildings Collateral BuildingsCollateral	59100000	USD
CY2014Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	448000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1590000	USD
CY2015Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	-12000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1741000	USD
CY2015Q2	lxrx	Clinical Trial Result Subsequent Event Impact ClinicalTrialResultSubsequentEventImpact	4100000	USD
CY2015Q2	lxrx	Common Stock Shares Authorized After Reverse Stock Split CommonStockSharesAuthorizedAfterReverseStockSplit	225000000	shares
CY2015Q2	lxrx	Common Stock Shares Authorized Before Reverse Stock Split CommonStockSharesAuthorizedBeforeReverseStockSplit	900000000	shares
CY2015Q2	lxrx	Convertible Debt Instrument Interest Rate Stated Percentage ConvertibleDebtInstrumentInterestRateStatedPercentage	0.0525
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2014Q4	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	34000000	USD
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	2000000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	161000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1769000	USD
CY2015Q2	lxrx	Land Collateral LandCollateral	2700000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	1092946	shares
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	21360	shares
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue	7.49
CY2014Q2	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	900000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1692000	USD
CY2015Q2	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	920000	USD
CY2014Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	940000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2398000	USD
CY2015Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	868000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1972000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	1891074	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2014Q4	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	5800000	USD
CY2015Q2	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	750000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2014Q4	lxrx	Symphony Contingent Payment Total SymphonyContingentPaymentTotal	11500000	USD
CY2014Q4	lxrx	Symphony Contingent Paymentin Shares SymphonyContingentPaymentinShares	666111	shares
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13064000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11291000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1035000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	316000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10120000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10807000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36274000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18672000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-63000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	98000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1390619000	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1394421000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4090000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3741000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1800000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4100000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1800000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3700000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	25000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	241000	USD
CY2014Q4	us-gaap	Assets Assets	471376000	USD
CY2015Q2	us-gaap	Assets Assets	415964000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	368987000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	313799000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37499000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27725000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137266000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9744000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9774000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-127522000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	128571000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	104000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	104000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26033000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56860000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27999000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55989000	USD
CY2014Q2	us-gaap	Contracts Revenue ContractsRevenue	627000	USD
	us-gaap	Contracts Revenue ContractsRevenue	799000	USD
CY2015Q2	us-gaap	Contracts Revenue ContractsRevenue	338000	USD
	us-gaap	Contracts Revenue ContractsRevenue	2130000	USD
CY2015Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	11708000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2015Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	100700000	USD
CY2015Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2014Q4	us-gaap	Debt Issuance Costs DebtIssuanceCosts	3400000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1618000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2218000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12679000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1198000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	601000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1590000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1741000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-750000	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	27710000	USD
CY2014Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29300000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17638000	USD
CY2015Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	18629000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-733000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-59000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5152000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10806000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6307000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12008000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	44543000	USD
CY2015Q2	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	4200000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	242000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2692000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3326000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-509000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-719000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	44000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	371000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	26000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-413000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2706000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2387000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	455000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	1655000	USD
	us-gaap	Interest Expense InterestExpense	3357000	USD
	us-gaap	Interest Paid Net InterestPaidNet	896000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3184000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	187358000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	184490000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	471376000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	415964000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44969000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	43571000	USD
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	49000	USD
	us-gaap	Licenses Revenue LicensesRevenue	154000	USD
CY2015Q2	us-gaap	Licenses Revenue LicensesRevenue	38000	USD
	us-gaap	Licenses Revenue LicensesRevenue	38000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	20167000	USD
CY2015Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	19255000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	87500000	USD
CY2015Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	87500000	USD
CY2015Q2	us-gaap	Mortgage Loans On Real Estate Carrying Amount Of Mortgages MortgageLoansOnRealEstateCarryingAmountOfMortgages	19300000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1591000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1208000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	41791000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70651000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49974000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55663000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-26028000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56863000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-28074000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56150000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	26787000	USD
	us-gaap	Operating Expenses OperatingExpenses	57536000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	27064000	USD
	us-gaap	Operating Expenses OperatingExpenses	55383000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26111000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-56583000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26688000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-53215000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4764000	USD
CY2015Q2	us-gaap	Other Assets Current OtherAssetsCurrent	7151000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3409000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3581000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	75000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23535000	USD
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23036000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	538000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	632000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	269000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	422000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	887000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	357000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20651000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	70505000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	480000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	162000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-27000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	61000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	60964000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1517000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	334000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1080000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	684000	USD
CY2014Q4	us-gaap	Real Estate Heldforsale RealEstateHeldforsale	23849000	USD
CY2015Q2	us-gaap	Real Estate Heldforsale RealEstateHeldforsale	23849000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	839000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	912000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21187000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45140000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20769000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41634000	USD
CY2014Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2015Q2	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1104252000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1160402000	USD
CY2015Q2	us-gaap	Revenues Revenues	376000	USD
	us-gaap	Revenues Revenues	2168000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4090000	USD
CY2014Q2	us-gaap	Revenues Revenues	676000	USD
	us-gaap	Revenues Revenues	953000	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	202073000	USD
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments	272739000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3741000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	162000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	284018000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	231474000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	170163000	USD
CY2014Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	116668000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	284018000	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	231474000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	61000	USD
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	183000	shares
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	237000	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2390000	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2747000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	887000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	357000	USD
CY2015Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3100000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	161000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	73518000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	73470000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103608000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103562000	shares

Files In Submission

Name	View Source	Status
0001062822-15-000032-index-headers.html	Edgar Link	pending
0001062822-15-000032-index.html	Edgar Link	pending
0001062822-15-000032.txt	Edgar Link	pending
0001062822-15-000032-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20150630.xml	Edgar Link	completed
lxrx-20150630.xsd	Edgar Link	pending
lxrx-20150630_cal.xml	Edgar Link	unprocessable
lxrx-20150630_def.xml	Edgar Link	unprocessable
lxrx-20150630_lab.xml	Edgar Link	unprocessable
lxrx-20150630_pre.xml	Edgar Link	unprocessable
lxrx630201510-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2015 Q2 Form 10-Q Financial Statement

#000106282215000032 Filed on August 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2015 Q2 Form 10-Q Financial Statement

#000106282215000032 Filed on August 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx